AMCO United Holding Limited 2025 Annual Report: Comprehensive Analysis and Investor Highlights

1. Financial Performance: Major Turnaround

• Revenue Surge: The Group reported a substantial increase in revenue to HK\$68.36 million in 2025, up from HK\$37.79 million in 2024, representing an 81% year-on-year growth.
• Profits Swing to Black: Profit for the year attributable to shareholders soared to HK\$59.12 million, reversing a loss of HK\$1.23 million in 2024. This dramatic turnaround was primarily driven by higher sales and significant gains in securities investment.
• Net Asset Value Growth: The Group’s net assets doubled to HK\$119.24 million (from HK\$60.13 million), and net asset value per share improved to 12.32 HK cents (from 6.21 HK cents).
• Earnings Per Share: Basic and diluted earnings per share rose sharply to 6.11 HK cents, compared to a loss per share of 0.13 HK cents in the prior year.
• Return on Sales: Impressive return on sales of 86.5%, versus a negative 3.3% last year, indicating strong operational efficiency and profitability.

2. Segmental Highlights and Strategic Developments

• Medical Devices Business: This segment saw a notable expansion in product offerings, including surgical instruments, orthopedic tools, imaging equipment, diagnostic devices, and sterilization products. The strategic diversification led to a marked increase in sales demand and revenue contribution. The company sees robust future demand, driven by global trends in healthcare and increased focus on personal health and well-being.
• Plastic Moulding Business: The business has been intentionally downsized and now contributes minimally to Group revenue, with its scale remaining stable.
• Money Lending Business: Stable income generation continues, with a net reversal of expected credit loss provisions amounting to HK\$10.6 million, compared to a provision of HK\$1.3 million last year.
• Securities Investment: The Group recorded a significant turnaround, posting a segment profit of HK\$50.1 million, compared to a loss of HK\$1.8 million in 2024. As at year-end, the Group held HK\$109 million in listed equity securities (30 stocks) and intends to diversify further to reduce concentration risk.

3. Balance Sheet and Capital Management

• Total Assets: Increased to HK\$227.89 million from HK\$159.33 million, reflecting a stronger financial position.
• Debt Position: Bond payables reduced to HK\$24.9 million (from HK\$30.9 million). Net debt to equity ratio improved significantly to 15% (from 44%), indicating greater financial stability and lower leverage.
• Liquidity: Current ratio improved to 2.6 (from 2.3), demonstrating enhanced ability to meet short-term obligations.

4. Investment Policy and Risk Management

• Internal Investment Policy: The Group maintains strict investment guidelines, focusing on efficient use of idle funds and generating stable returns within acceptable risk levels. Investments are limited to listed securities, bonds, funds, insurance products, and bank deposits. Speculative derivative trading and unlisted securities are strictly prohibited.
• Governance and Oversight: Investment decisions below 5% of market cap or total assets are approved by an executive team; larger investments require Board approval. The Group employs ongoing risk management and internal controls, with regular performance reviews and monitoring of investments.
• Credit Risk Management: The Group has robust policies for screening loan applicants, requiring asset/income proof and regular credit reviews. A reversal of impairment losses on loan and interest receivables was recorded, reflecting improved credit quality and successful collections.

5. Corporate Governance and ESG Focus

• Governance: AMCO has fully complied with Hong Kong’s Corporate Governance Code, with Board and committee oversight on financial reporting, risk management, and investments.
• ESG Initiatives: The Group is committed to reducing its carbon footprint and promoting resource efficiency, with environmental strategies implemented throughout its operations. Further details are available in the separate ESG report.
• Shareholder Communication: The company maintains transparent communication with shareholders, including timely dissemination of reports and notices. No dividend was declared for the year.

6. Noteworthy Risks & Strategic Outlook

• Market and Strategic Risks: The Group is exposed to changes in global financial markets, credit, and liquidity risks, as well as operational and strategic risks due to rapid market changes. Active measures are in place to monitor and adapt to these risks.
• Growth Prospects: The Board remains optimistic about the Medical Devices segment, citing global healthcare trends and increased demand for advanced medical products. The company will continue reallocating resources to high-potential segments and maintain financial discipline to preserve liquidity and shareholder value.
• Share Option Scheme: The existing scheme expired in June 2025, with no new share options granted during the year.

7. Shareholder-Sensitive and Potentially Price-Moving Information

• Turnaround from Loss to Profit: The swing to a substantial profit and strong growth in revenue and assets is likely to be viewed very positively by the market, potentially supporting a re-rating of the company’s shares.
• Significant Gains from Securities Investment: The large profit from securities investment is noteworthy, but also highlights exposure to market volatility. Plans to diversify the investment portfolio could reduce risk but may also affect future returns.
• Medical Devices Segment Expansion: The successful diversification and expansion in this segment aligns with global healthcare trends and could drive future growth and valuation.
• No Dividend Declared: While profitability improved, the Board did not recommend a dividend, possibly to retain capital for strategic initiatives and further investments.
• Improved Credit Quality: The net reversal of impairment losses in the money lending business indicates effective credit risk management and supports the sustainability of this income stream.

8. Other Regulatory and Statutory Disclosures

• No director or chief executive held any interests or short positions in shares, underlying shares, or debentures of the company or its associated corporations during the year.
• No equity-linked agreements (other than expiring share options) or significant related party transactions were reported.
• The Company maintained sufficient public float and was not aware of any non-compliance with laws or regulations during the period.

Conclusion

AMCO United Holding Limited’s 2025 annual report reveals a company in significant transformation, with a pronounced return to profitability, robust growth in core business segments, and a solid balance sheet. The expansion of the Medical Devices business, exceptional gains from securities investments, and prudent risk management strategies position the Group for continued growth. However, investors should remain mindful of the inherent risks associated with market volatility in the investment portfolio and the Group’s ongoing resource allocation strategies.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions.

View AMCO UNITED Historical chart here